ClinicalTrials.gg
CompletedNCT03337035Updated Mar 4, 2020

Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children

A Phase 1 interventional study of intranasal oxytocin and oral probiotics in Autism Spectrum Disorder, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 3 Years to 25 Years. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Massachusetts General Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2019, 7 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
3 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 37 studies in Autism Spectrum Disorder by Massachusetts General Hospital — 3 open to participants now, 4 under way, none of them phase 3. Autism Spectrum Disorder · Massachusetts General Hospital.

Enrollment
12th of 27
35 · median 30
Started
2018
with 3 others
Phase 1
Only one
of the 37
Registered
23rd of 37
by date

Among the 37 studies in Autism Spectrum Disorder by Massachusetts General Hospital, this one is the 12th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2018, is the only one in phase 1, and was the 23rd registered.

Autism Spectrum Disorder

1,732 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

3 of the 37 studies in Autism Spectrum Disorder by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.

This study: 3 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Autism Spectrum Disorder by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Because oral probiotics reported to potentially induce endogenous Oxytocin, and Oxytocin has been reported to improve social behaviors, the investigators will conduct a pilot trial to compare the effects of probiotics and Oxytocin on social behavioral changes in ASD children. Additionally, the investigators will check oxytocin levels, and perform brain fMRI in some subjects, in order to determine which treatment is more efficient, sustainable, and practical, and whether both treatments in combination are better than either treatment alone. If the trial is conclusive, the investigators will conduct a trial in large scale to understand more the mechanism of ASD behaviors and corresponding effective interventions.

Read the detailed description

This study description is in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines that are published for the evaluation of randomized controlled trials. This clinical trial is a randomized, double-blind placebo controlled study. Subjects will be randomized to 2 groups:

Phase 1: a. oral placebo, and b. oral probiotics; Phase 2: a. intranasal Oxytocin(OXT) + oral placebo, and b. intranasal OXT + oral probiotics

The treatment will proceed for a total of 28 weeks. In the first phase (16 weeks), all the patients will be randomly and proportionally divided into two groups: Group A (30 subjects) receives oral probiotics while Group B (30 subjects) receives an oral placebo. In the second phase, subjects in Group A and Group B will continue their respective oral probiotics or placebo administration as in Phase 1. In addition, both groups will be simultaneously administered with intranasal OXT spray.

Testing will be performed 3 times total (before, during, and after treatment). The tests include behavioral surveys, cognitive tests, clinical autonomic tests, and blood tests for oxytocin levels. Investigators plan to select up to 10 subjects from each group to conduct a series of MRI studies at week 0, week 16 and week 28.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Probiotics, Oxytocin
04

Who can participate

Ages eligible
3 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 3-25years old;
  2. Pre-existing diagnosis of autism; subjects may be asked to provide documentation confirming diagnosis by criteria, ADOS, ADI-R, or other clinical forms
  3. A care provider who can reliably bring the participant to study visits;
  4. No planned changes in medications or psychosocial interventions during trial (stable medications within the last 2 weeks);
  5. Willingness to provide blood samples

Exclusion criteria

Exclusion Criteria:

  1. Pregnant woman (before or during the study).
  2. Comorbidity of other neurological and/or psychiatric disorders such as unstable seizures, schizophrenia, schizoaffective disorder, bipolar disorders or history of substance abuse.
  3. Psychotropic medication use
  4. Subjects with active cardiovascular disease that is not controlled by medication.
  5. Oxytocin, antibiotic, or probiotic use within the last 30 days.
  6. Regular nasal obstruction or nosebleeds
  7. Significant hearing, vision, or motor impairments
  8. Habitual consumption of large volumes of water
  9. Started taking new medications within the last 2 weeks
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Active comparator
    oral probiotics and oxytocin spray

    Subjects will receive oral probiotics, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.

    Drug: intranasal oxytocin · Dietary Supplement: oral probiotics

  • Placebo comparator
    oral placebo and oxytocin spray

    Subjects will receive oral placebo, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.

    Drug: intranasal oxytocin · Dietary Supplement: oral placebo

Interventions

  • DrugOxytocinStudies of OxytocinOxytocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    4-24 IU per day, dosage gradually increases

    Also known as: Novartis Syntocinon

  • Dietary supplementoral probiotics

    200 million cfu per day

  • Dietary supplementoral placebo

    2 pills per day

06

What researchers measure

Primary outcomes

  1. Social Responsiveness Scale (SRS) Edition 2

    social communication and behavior - The scoring is based on T-score which is based on the sum of responses as follows (76 to higher - severe, 66 to 75- moderate deficiencies, 60 to 65 - mild deficiencies, 59 and below is not clinically significant for ASD).

    Time frame: change from baseline at 0, 16, and 28 weeks

  2. Aberrant Behavior Checklist (ABC) Edition 2

    social behavior test - The total score is calculated based on 5 sub-scales (Irritability, Social Withdrawal, Stereotypic Behavior, Hyperactive/Noncompliance, and Inappropriate Speech). There are 58 questions that are scored on a 0-3 scale 0 -"not at all a problem", 1- "the behavior is a problem but slight in degree", 2- "the problem is moderately serious" and 3- "the problem is severe in degree". Based on this sub-scores are calculated and added to get the total score.

    Time frame: change from baseline at 0, 16, and 28 weeks

Secondary outcomes

  1. Neuroinflammation and Oxytocin levels

    neuroendocrine biomarker measured in blood ( Melatonin, Oxytocin, Tumour Necrosis Factor alpha, testosterone and Interleukin 6)

    Time frame: change from baseline at 0, 16, and 28 weeks

  2. structural MRI

    The software Freesurfer will be used to calculate volume of brain regions and diffusion parameters (e.g. fractional anisotropy and mean diffusivity) from structural T1 and diffusion tensor images respectively. T-tests will be applied for group comparisons.

    Time frame: change from baseline at 0, 16, and 28 weeks

  3. Functional MRI (resting state)

    Correlation analysis will be used to calculate the connectivity across different brain regions. T-tests will be used for group comparisons.

    Time frame: change from baseline at 0, 16, and 28 weeks

  4. Functional MRI (task based)

    General linear modeling will be used to calculate brain responses to the tasks. T-tests will be used for group comparisons.

    Time frame: change from baseline at 0, 16, and 28 weeks

  5. Autonomic indices 1

    Blood volume pulse

    Time frame: change from baseline at 0, 16, and 28 weeks

  6. Autonomic indices 2

    heart rate

    Time frame: change from baseline at 0, 16, and 28 weeks

  7. Autonomic indices 3

    peripheral skin temperature

    Time frame: change from baseline at 0, 16, and 28 weeks

  8. Autonomic indices 4

    skin electrodermal activity

    Time frame: change from baseline at 0, 16, and 28 weeks

  9. Autonomic indices 5

    blood oxygen saturation

    Time frame: change from baseline at 0, 16, and 28 weeks

  10. Microbiome

    16s metagenomic sequencing of the microbiome

    Time frame: change from baseline at 0, 16, and 28 weeks

  11. Eye tracking and Behavioral task (joint attention)

    joint attention - Conduct T-tests and calculate P values for total and average fixation values for each area of interest

    Time frame: change from baseline at 0, 16, and 28 weeks

  12. Eye tracking and behavioral task (emotion response)

    emotion response - The accuracy and reaction time will be calculated for each time point. Then an ANOVA will be used to compare the results.

    Time frame: change from baseline at 0, 16, and 28 weeks

  13. Eye tracking and behavioral task (eye behavior)

    eye behavior - Conduct T-tests and calculate P values for total and average fixation values for each area of interest

    Time frame: change from baseline at 0, 16, and 28 weeks

07

Study locations

1 site
  • Massachusetts General Hospital
    Charlestown, Massachusetts 02129, United States
08

References and documents

Publications

  • Sherman HT, Liu K, Kwong K, Chan ST, Li AC, Kong XJ. Carbon monoxide (CO) correlates with symptom severity, autoimmunity, and responses to probiotics treatment in a cohort of children with autism spectrum disorder (ASD): a post-hoc analysis of a randomized controlled trial. BMC Psychiatry. 2022 Aug 8;22(1):536. doi: 10.1186/s12888-022-04151-3. PubMed 35941573 ↗
  • Kong XJ, Liu J, Li J, Kwong K, Koh M, Sukijthamapan P, Guo JJ, Sun ZJ, Song Y. Probiotics and oxytocin nasal spray as neuro-social-behavioral interventions for patients with autism spectrum disorders: a pilot randomized controlled trial protocol. Pilot Feasibility Stud. 2020 Feb 12;6:20. doi: 10.1186/s40814-020-0557-8. eCollection 2020. PubMed 32082606 ↗

Individual participant data

Plan to share: No — There is no plan to share data with researchers not involved in this study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Oct 2019, 10 months.

Of 35 phase 1 interventional studies under Autism Spectrum Disorder, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 27. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2017
First posted
Nov 8, 2017
StartActual
Dec 1, 2018
Primary completionActual
Oct 2, 2019
CompletionActual
Oct 2, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03337035
Responsible party
Xuejun Kong,MD (Research Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Nov 8, 2017
Start date
Dec 1, 2018
Primary completion
Oct 2, 2019
Completion
Oct 2, 2019
Last update
Mar 4, 2020

Study contacts

Xue-Jun Kong, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion